For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Treatment-Associated Suicidal Ideation and Adverse Effects in an Open, Multicenter Trial of Fluoxetine for Major Depressive EpisodesPerlis R.H.a · Beasley Jr. C.M.b · Wines Jr. J.D.c, · Tamura R.N.b · Cusin C.a,1 · Shear D.a · Amsterdam J.d · Quitkin F.†e · Strong R.E.f, 1 · Rosenbaum J.F.a · Fava M.a
aDepression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, Mass., bLilly Research Laboratories, Eli Lilly & Co., Indianapolis, Ind., cMcLean Hospital and Harvard Medical School, Belmont, Mass., dDepression Research Unit, University of Pennsylvania Medical Center, Philadelphia, Pa., eNew York State Psychiatric Institute, New York, N.Y., and fUniversity of Utah, Salt Lake City, Utah, USA
Background: Some reports suggest that a subset of depressed patients may experience suicidality – that is increase or emergence of suicidal ideation (SI) or behavior – after initiation of an antidepressant. The time course and clinical correlates of this phenomenon have not been characterized in detail. Method: We conducted a secondary analysis of a multicenter, prospective, open, 12-week trial of fluoxetine 20 mg in outpatients with nonpsychotic major depressive episodes. Adverse effects and other clinical features associated with the emergence of suicidality, defined using item 3 of the Hamilton Depression Rating Scale, were examined using Cox regression models. Results: Among 414 subjects without SI at baseline, 59 (14.3%) reported SI on at least 1 postbaseline visit. In a Cox regression, emergence of activation and worsening of depression severity were independently associated with emergence of SI, along with female gender, younger age and having thoughts that life was not worth living prior to treatment. Treatment response and remission were significantly less likely among subjects who developed SI. Conclusions: New SI was relatively common in this trial of fluoxetine and associated with the emergence of activation and overall symptomatic worsening. Whether prophylaxis against or aggressive treatment of adverse events can decrease emergence of SI merits further study.
© 2007 S. Karger AG, Basel